China’s Abogen Biosciences raises $300m in Series C+ round

Vaccine products

Chinese mRNA vaccine developer Suzhou Abogen Biosciences Co Ltd has raised as much as $300 million in its Series C+ round of funding, per an announcement.

SoftBank Vision Fund alongside returning investor 5Y Capital jointly led the funding.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter